tiprankstipranks
Advertisement
Advertisement

CH:MOLN Stock Latest News

Clear Street transfers coverage on Molecular Partners, keeps Buy rating
The FlyClear Street transfers coverage on Molecular Partners, keeps Buy rating
8d ago
MOLN
Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating
PremiumRatings
Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating
18d ago
MOLN
Molecular Partners doses first patients in MP0317 combination study
PremiumThe Fly
Molecular Partners doses first patients in MP0317 combination study
2M ago
MOLN
Molecular Partners Reaffirmed at Buy as Analyst Cites MP0712 Progress and Keeps $12 Price Target Unchanged
PremiumRatings
Molecular Partners Reaffirmed at Buy as Analyst Cites MP0712 Progress and Keeps $12 Price Target Unchanged
2M ago
MOLN
Molecular Partners, Orano Med doses first patient in MP0712 study
PremiumThe Fly
Molecular Partners, Orano Med doses first patient in MP0712 study
2M ago
MOLN
Molecular Partners to hold trial-in-progress presentations on Phase 1/2a study
PremiumThe FlyMolecular Partners to hold trial-in-progress presentations on Phase 1/2a study
3M ago
MOLN
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
Premium
Ratings
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
4M ago
MOLN
Molecular Partners publishes MP0317 clinical data in Nature Cancer
Premium
The Fly
Molecular Partners publishes MP0317 clinical data in Nature Cancer
4M ago
MOLN
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
PremiumRatings
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
5M ago
MOLN
Molecular Partners announces presentation of preclinical data at AACR
PremiumThe Fly
Molecular Partners announces presentation of preclinical data at AACR
5M ago
MOLN
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
PremiumRatings
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
6M ago
MOLN
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
PremiumRatings
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
6M ago
MOLN
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
PremiumRatingsBuy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
6M ago
MOLN
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
Premium
Ratings
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
7M ago
MOLN
Molecular Partners enters Radio-DARPin therapeutics pact with Eckert & Ziegler
Premium
The Fly
Molecular Partners enters Radio-DARPin therapeutics pact with Eckert & Ziegler
7M ago
MOLN
Molecular Partners presents first imaging, dosimetry data of MP0712
PremiumThe Fly
Molecular Partners presents first imaging, dosimetry data of MP0712
7M ago
MOLN
Molecular Partners initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Molecular Partners initiated with a Buy at H.C. Wainwright
8M ago
MOLN
Molecular Partners provided update on latest progress, 2026 milestones
PremiumThe Fly
Molecular Partners provided update on latest progress, 2026 milestones
8M ago
MOLN
Molecular Partners forms Scientific Advisory Board
PremiumThe Fly
Molecular Partners forms Scientific Advisory Board
9M ago
MOLN
Promising Pipeline and Strategic Focus Drive Buy Rating for Molecular Partners
PremiumRatingsPromising Pipeline and Strategic Focus Drive Buy Rating for Molecular Partners
9M ago
MOLN
Molecular Partners price target lowered to CHF 3 from CHF 3.50 at JPMorgan
Premium
The Fly
Molecular Partners price target lowered to CHF 3 from CHF 3.50 at JPMorgan
9M ago
MOLN
Molecular Partners price target lowered to $3.75 from $4 at JPMorgan
Premium
The Fly
Molecular Partners price target lowered to $3.75 from $4 at JPMorgan
9M ago
MOLN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >